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INTRODUCTION 
 
Hepatopulmonary syndrome (HPS) is said to exist when a combination of the 
following 
three are present:  
1) Evidence of chronic liver  disease   complicated  by portal 
hypertension (With or without cirrhosis),   
2) Arterial hypoxemia with partial pressure of oxygen (PaO2) in 
arterial blood <80 mmHg or alveolar-arterial   (A-a) oxygen 
gradient >20 mmHg   
3) Intrapulmonary vascular dilatations documented on contrast 
enhanced echocardiography or technetium99m labeled albumin 
scanning.  
Some patients with intrapulmonary vascular dilatations may not develop 
hypoxemia and is referred to as intrapulmonary vascular dilatation syndrome 
(IPVDS) or sub-clinical HPS. 
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                The predominant abnormality identified are intrapulmonary 
vascular dilatations (IPVDs), occurring at capillary and precapillary levels 
and these serve as functional shunts.  
                 Anatomic arteriovenous anastomoses, pleural spider naevi, 
ventilation perfusion abnormalities, impaired hypoxic pulmonary 
vasoconstriction and portopulmonary vascular shunts are known to contribute.  
Evidence till date suggests that shunting of blood through IPVDs is the 
most important cause of hypoxemia in HPS, and like other functional 
shunts it responds to supplemental oxygen. Two-dimensional transthoracic 
echocardiography using agitated saline or indocyanine green as contrast is the 
most commonly used method for identifying these shunts. 
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REVIEW OF LITERATURE 
Hypoxemia is a common clinical manifestation in patients with liver cirrhosis. 
It may result from the common cardiopulmonary diseases such as pneumonia, chronic 
obstructive pulmonary disease, congestive heart failure and pulmonary edema.  
            A relationship between cirrhotic liver and lung was first described by 
Fluckiger1 in 1884 based on the observation of a woman with cirrhosis, cyanosis and 
clubbed digits. Several authors have since confirmed this finding. In 1977, Kennedy 
and Knudson coined the term “hepatopulmonary syndrome” to describe this entity2. 
Although more prevalent in patients with cirrhosis, HPS has also been reported in 
association with other liver diseases like the Budd-Chiari syndrome and 
schistosomiasis. 
                       Further, HPS has been reported in non cirrhotic portal hypertension, 
suggesting thereby that portal hypertension may play a role in the pathogenesis 
independent of liver dysfunction. A study from Calcutta mentioned an occurrence of 
9.5% in patients with non cirrhotic portal fibrosis, a condition with essentially normal 
liver function. In the light of this evidence, the criteria for HPS need to be modified to 
a triad of portal hypertension, hypoxemia and intrapulmonary vascular dilatations, and 
it would be more appropriate to term it the “portopulmonary syndrome”. 
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Definition and Demographics 
 Hepatopulmonary syndrome (HPS) is characterized by the triad of 
advanced liver disease, arterial hypoxemia (arterial oxygen tension, PaO2 < 80 mmHg 
or alveolar arterial oxygen gradient > 20 mmHg at room air), and intrapulmonary 
vascular dilatation3-5. The prevalence in the setting of cirrhosis ranges from 4% to 
17%6-8.  
                       The correlation between the severity of liver disease and the existence 
of HPS remains controversial. One prevailing concept is that the development of 
intrapulmonary vascular dilatation is related to the progression of liver dysfunction 
and correlates with systemic vasodilatation and hyperdynamic circulation9. 
                          In a prospective study, Vachiery et al10 suggested that cirrhotic 
patients with HPS were characterized by a higher Child-Pugh’s score and a higher 
hepatic venous pressure gradient. However, other studies did not support this finding11, 
12. There may be factors other than the severity of liver disease that are important for 
the development of HPS. 
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Mechanisms of Hypoxemia 
 The increased cardiac output and IPVD are thought to be 
important factors in the development of the HPS. Patients with liver cirrhosis and the 
HIPS have increased cardiac output of about 7L/min. About 20% to 70% of this is 
conducted by the IPVD resulting in a short transit time for the blood in the lungs. 
When breathing a normal room air, the 0 2 drive is enough to oxygenate the red blood 
cells at the center of the normal pulmonary vessels  
                                   In patients with the HPS who have dilated capillaries oxygen 
molecules from adjacent alveoli cannot diffuse to oxygenate hemoglobin in 
erythrocytes at the center stream of venous blood. This inadequate oxygenation is 
enhanced by the short transit time of the hyperdynamic circulation, which does not 
provide the red blood cells enough time in contact with the alveoli to acquire good 
amount of oxygen.  
                                   When such a patient is in the upright position a 
disproportionately larger amount of the blood in the pulmonary circulation 
preferentially flows to the dilated vessels in the hypoventilated lung bases. This further 
enhances diffusionperfusion impairment leading to platypnea and orthodeoxia. Unlike 
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what occurs in true anatomical shunts, supplemental oxygen provides enough driving 
pressure to partially overcome the relative diffusion defect in HPS. 
 Exercising patients with cirrhosis or HPS while breathing room 
air or 100% oxygen had caused further impairment of oxygenation, development of 
wider alveolo-arterial oxygen gradient and larger shunt fraction. This may be 
explained at least in part, by the shortened transit time. The effect of exercise is more 
pronounced in patients with the HPS who already demonstrate a severe reduction in 
aerobic capacity beyond the levels seen in cirrhotics without the syndrome  
                               Normal pulmonary vascular tone is essential for maintaining 
adequate ventilation / perfusion equation that maintain normal oxygenation. A high or 
low tone disturbs the equation and leads to hypoxemia. Although the IPVD causing 
diffusion-perfusion impairment is considered to be the most important factor 
underlying impaired gas exchange and resulting in severe hypoxemia characteristic of 
the HPS, it is not enough alone to diagnose HPS as it may not be associated with 
severe hypoxemia. 
 Hypoxemic pulmonary vasoconstriction has a fundamental role 
in maintaining normoxemia by diverting blood away from hypoventilated areas in the 
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lungs; impairment of this pulmonary vasoconstriction in response to hypoxemia by an 
unknown mechanism - is hypothesized to be the third element precipitating the HPS  . 
Pathogenesis 
 
 
Fig. 1.— Working model of molecular alterations in the pulmonary microcirculation 
in experimental hepatopulmonary syndrome (HPS).  
a) In the normal microvasculature, a balance of vasoconstrictive and vasodilatory 
factors, including paracrine endothelin (ET)-1-mediated vasoconstriction through the 
ETA receptor  on smooth muscle cells (SMCs) and ET-1-mediated vasodilatation 
8 
 
mediated through the ETB receptor  linked to endothelial nitric oxide synthase (eNOS) 
in endothelial cells (ECs), maintain tone.  
b) During the development of HPS, a number of alterations, both directly and 
indirectly relatedto hepatic injury and portal hypertension result in the production or 
release of mediators into the venous circulation, where they influence the pulmonary 
microcirculation. Increased expression of pulmonary endothelial ETB receptors and 
increased hepatic production and release of ET-1 contribute to an increase in eNOS 
expression and enhanced nitric oxide (NO) production in the microvascular 
endothelium during the initiation of HPS. Tumour necrosis factor (TNF)- -mediated 
accumulation of intravascular macrophage-like cells also occurs after chronic common 
bile duct ligation. Haem oxygenase (HO)-1 and inducible nitric oxide synthase (iNOS) 
expression increase in these cells and contribute to the progression of HPS. CO: 
carbon monoxide.  
                     The exact pathogenesis of HPS is not completely understood. Common 
bile duct ligation (CBDL) in rat is the only recognized model for the study of HPS13. It 
is interesting to note that in the animal model of partial portal vein ligation (a model of 
portal hypertension but without cirrhosis), in which the rats develop a similar degree 
of portal hypertension and hyper dynamic circulation as CBDL rats, there is no 
detectable alteration of the pulmonary vasculature14-16. Therefore, it is possible that 
both hepatic injury and portal hypertension are required for the development of HPS.  
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                   Castro and Krowka5 proposed that an imbalance between vasoconstrictors 
and vasodilators in the pulmonary vasculature contributed to the pathogenesis of HPS. 
The most extensively investigated vasodilator is nitric oxide (NO). Increased levels of 
exhaled nitrite and nitrate, the metabolites of NO, are found in patients with HPS; 
levels return to normal after liver transplantation, with normalization of oxygen 
saturation. In rats that develop HPS, the level of endothelial NO synthase (eNOS) 
protein is increased in the region of pulmonary of iNOS in HPS cannot be completely 
ruled out.  
                   In addition to NO, other vasoactive substances have also been suggested to 
play a role in the development of HPS. Increased hepatic expression and plasma levels 
of endothelin-1 (ET-1) have been observed in both experimental and human cirrhosis. 
                   Luo et al15reported that increased ET-1 production correlated with 
intrapulmonary molecular and gas exchange abnormalities, and suggested that ET-1 
may contribute to the pathogenesis of HPS.  
                   Thereafter, the same group of investigators also found increased 
endothelin B (ETB) receptor expression in the pulmonary vasculature from cirrhotic 
animals. It is known that ET-1 may exert an autocrine vasodilatory effect by 
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increasing eNOS activity and subsequent NO production via the ETB receptors on 
vascular endothelial cells.  
                   Accordingly, Luo et al15 suggested that, in response to the increased 
circulating ET-1 level in cirrhosis, an increase in pulmonary vascular ETB receptors 
may result in increased eNOS activity and NO production, with subsequent 
intrapulmonary vasodilatation. The factors that contribute to increased ETB receptor 
expression in pulmonary vasculature in cirrhotics have not been completely 
established. 
                   Hyper dynamic circulation-related increase in pulmonary blood flow with 
a flow-mediated alteration in vascular ETB receptor expression may play a role. Other 
factors such as increased cytokine production, particularly of interleukin-1, and 
hypoxia that are known to alter in cirrhosis may also modulate intrapulmonary ETB 
receptor expression26, 27.  
                   Carbon monoxide (CO) is another vasoactive substance that has recently 
been evaluated for its role in the pathogenesis of HPS28. CO can cause vasodilatation 
by the cyclic guanosine monophosphate (cGMP) independent pathway, possibly by 
directly activating KCa channels29. CO is generated during the degradation of heme by 
heme oxygenase (HO), which has constitutive and inducible isoforms. HO-1 is an 
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inducible protein that is expressed in a number of cell types in the lung, most notably 
alveolar, bronchial epithelium and inflammatory cells, including macrophages.  
                   Increased NO production in cirrhosis has been shown to induce up 
regulation of intrapulmonaryHO-1 expression, which may be involved in the 
pathogenesis of HPS. Zhang et al31 reported that increased CO production induced by 
pulmonary HO-1 over expression in cirrhotic rats may contribute to the progression of 
HPS. They also suggested that the increase in pulmonary HO-1 protein may be caused 
by the accumulation of intravascular macrophages in the early stage after bile duct 
ligation when cirrhosis and hemodynamic changes have not completely developed. 
Thereafter, increased CO production can be observed with the development of HPS to 
worsen gas exchange. However, the mechanism of macrophage accumulation in the 
pulmonary vasculature is not understood. Increased circulating tumor necrosis factor 
may be an important triggering factor31, 32. 
 
Clinical Manifestations 
 
                   Since intrapulmonary vascular dilatation leads to ventilation-perfusion 
mismatch, the major clinical manifestation of HPS is impaired oxygenation, which 
varies from a mild increase in the alveolar-arterial oxygen gradient to severe arterial 
hypoxemia.  
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                   As the vascular abnormalities predominate in the middle to lower lung 
fields, gravitational effects may increase the blood flow to worsen the ventilation-
perfusion mismatch and, finally, result in deterioration in arterial oxygenation when in 
the upright position. Orthodeoxia, defined as arterial deoxygenation accentuated in the 
upright position versus the supine position, is a characteristic feature of HPS.  
                   A cutoff value for Orthodeoxia is defined by a PaO2 decrease of 5% or 
more or 4 mmHg or more from the supine to upright position. Its reported prevalence 
ranges from 20% to 80% in patients with HPS. Krowka and Cortese36 found that the 
mean drop in PaO2 was 12 mmHg when patients stood from the supine position.  
                   Clubbed fingers are common, and the presence of spider nevi has been 
suggested as one of the most sensitive clinical markers. In cirrhotic patients with 
portal hypertension, spider nevi, clubbed fingers and hypoxemia are highly suggestive 
of HPS. 
Diagnosis 
                   Several causes other than HPS may be involved in cirrhosis presenting 
with hypoxemia, such as intrinsic cardiopulmonary abnormalities, pulmonary 
atelectasis, pneumonia, ascites, pulmonary edema or hepatic hydrothorax.  
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                   In cirrhotic patients with clinical symptoms and arterial blood gas 
compatible with hypoxemia, a chest film must first be taken to rule out reversible 
conditions. Pulmonary function test should be performed to rule out the common 
intrinsic pulmonary disorders such as chronic obstructive pulmonary disease. HPS 
should be suspected in patients who have persistent hypoxia after a normal chest film 
or after optimal treatment of the underlying conditions.  
                   Contrast enhanced echocardiography is the preferred screening test for 
HPS. It uses agitated saline or indocyanine green to produce micro bubbles at least 15 
µm in diameters that are then injected intravenously. Under normal circumstances, 
these micro bubbles are trapped in the pulmonary microvasculature and then absorbed. 
In patients with intracardiac or intrapulmonary shunting, these micro bubbles are seen 
in the left heart.  
                   Differentiation between intracardiac and intrapulmonary shunting is based 
on the timing of when these bubbles are found in the left heart. In intracardiac right-to-
left shunts, these bubbles appear in the left heart in 3 heartbeats after they appear in 
the right heart. In intrapulmonary shunts, these bubbles appear in 4–6 heartbeats.  
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                   A recent study by Vedrinne et al37revealed that transesophageal 
echocardiography is more sensitive than transthoracic echocardiography in 
demonstrating intrapulmonary shunting.  
                   However, there are several shortcomings of contrast enhanced 
echocardiography. First, it cannot quantify the shunting. Second, it cannot differentiate 
between intrapulmonary vascular dilatation and direct arteriovenous communication. 
Third, even though contrast echocardiography is highly sensitive for HPS, it lacks 
specificity. 
                   Proportions of cirrhotic patients with positive results on contrast 
echocardiography have normal arterial blood gas and do not fulfill the diagnostic 
criteria for HPS. Lastly, in patients with concomitant intrinsic lung diseases, the 
contribution of HPS to arterial desaturation cannot be defined by contrast 
echocardiography. 
                   In order to overcome the disadvantages of contrast echocardiography, the 
role of 99mtechnetium macro aggregated albumin (Tc-99m MAA) lung perfusion scan 
in diagnosing HPS was assessed. The albumin macroaggregates are more than 20 µm 
in diameter. Under normal circumstances, they are entrapped in the pulmonary 
vasculature. In patients with intracardiac or intrapulmonary shunts, these albumin 
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macroaggregates can escape the pulmonary vasculature and be taken up by other 
organs. In normal healthy patients, less than 5% of isotope can be quantified in the 
brain. 
                   In HPS patients, the fraction is more than 6%. In a cohort study, Tc-99m 
MAA lung perfusion scan identified all cirrhotic patients with HPS who presented 
with moderate to severe hypoxemia, and yielded negative results in those without HPS 
and in all non-cirrhotic hypoxic patients with intrinsic lung disease. Accordingly, Tc-
99m MAA scan may be useful for the diagnosis of HPS.  
                   In cirrhotic patients with concomitant intrinsic pulmonary disorders, the 
fraction of Tc-99m MAA scan can define the significance of the HPS in clinical 
hypoxemia. That study also showed an inverse correlation between the magnitude of 
the shunt fraction and arterial oxygen saturation.  
                   The major disadvantage of Tc-99m MAA scan is that it cannot 
differentiate intracardiac from intrapulmonary shunting. The shunt fraction of Tc-99m 
MAA scan also does not correlate with the response of PaO2 after 100% oxygen is 
supplied.  
     Pulmonary angiography is an invasive procedure that can show the 
appearance of the pulmonary vasculature. A pulmonary arteriography study in patients 
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with HPS revealed 2 vascular patterns, the type I or diffuse pattern and the type II or 
focal pattern.  
                   The minimal diffuse type I pattern is characterized by the presence of 
normal vessels or finely diffuse spidery vascular abnormalities. The advanced type I 
pattern is characterized by a diffuse spongy or blotchy appearance.  
                   The type II pattern is a less frequent finding. Patients with advanced type I 
or type II patterns show a poor response to 100% oxygen. Due to the focal 
involvement of the pulmonary vasculature and poor treatment response, patients with 
a type II pattern should be considered for embolization therapy.  
        Pulmonary angiography should, because of its invasiveness, only be 
reserved for patients with HPS who respond poorly to 100% inspired oxygen and in 
whom vascular embolotherapy can be performed at the same time to obliterate the 
arteriovenous communications.  
CT- Scan: It is used for finding other disease processes which cause hypoxemia. 
However, in HPS, CT scanning of lungs may show dilatation of peripheral pulmonary 
vasculature. 
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Treatment and Prognosis 
                   As the major clinical manifestation of HPS is arterial hypoxemia, 
supplying oxygen is the first line of therapy. Similar to oxygen therapy in patients with 
chronic obstructive pulmonary disease, long-term oxygen supply prolongs survival in 
patients with HPS. In patients with poor response to 100% oxygen, pulmonary 
angiography with embolization therapy is an alternative. 
Several medical treatments including almitrine bismesylate, indomethacin, tamoxifen, 
somatostatin analogues, sympathomimetics, ß-blockers, Methylene blue and plasma 
exchange have been used in the treatment of HPS with disappointing results5, 12, 40. 
                    Small series have reported beneficial responses to pharmacological agents 
such as almitrine,methylene blue,and even garlic powder (Allium sativum), which 
increase pulmonary vascular resistance, pulmonary artery pressures, and arterial 
oxygenation. Indomethacin is used with the logic of inhibition of prostaglandin 
production which has a putative role of vasodilatation. The results of research about 
indomethacin have been inconclusive. 
                    Methylene blue is a potent inhibitor of NO and its intracellular mediator, 
gunaylate cyclase. In a study which was performed on 7 patients with HPS and 
advanced liver cirrhosis, it had several effects: increase of PO2, decrease of ΔP(A-
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a)O2, decrease of shunt fraction and increase of mean pulmonary artery pressure, 
increase of pulmonary vascular resistance and lowered cardiac output. Beneficial 
effects on gas exchanged continued up to 10 hours. Methylene blue is potentially 
effective for treatment of HPS although transiently. It might be used in the post-OP 
period of liver transplantation in cases who have transient hypoxemia, however its 
routine and long term use is not recommended due to lack of  adequate data regarding 
side effects in long term periods, beneficial effects of No in body defense and bluish 
discoloration of mucous membranes and secretions57.  
 Interventions other than liver transplantation: 
 Embolotherapy: It is recommended that pulmonary angiography be done for 
those HPS patients who respond poorly to breathing 100% oxygen i.e., PaO2<150-
200mmHg. If coil type II vascular lesions are diagnosed, embolotherapy with 22-
coil spring devices must be tried first, since it is seen that this group of HPS 
patients responds poorly to liver transplantation due to responsible A-V 
communications which are less amenable to closure after liver transplantation.  
Portal decompression wtih transjugular intrahepatic portosystemic shunt 
(TIPS):  Regarding probable role of portal hypertension in the pathogenesis of 
HPS, portal decompression is suggested as a potential way for improving HPS. 
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There is controversy regarding above mentioned beneficial effects of the above 
mentioned technique on HPS. Some studies confirmed and HPS others ruled out 
usefulness of TIPS. Overall, TIPS could be considered as a palliative treatment 
and/or as a bridge to orthotopic liver transplantation in severe hypoxemic HPS 
patients since liver transplantation may be dangerous in profound hypoxemia. More 
researches are needed undoubtfully. 
                 In a retrospective analysis in 22 patients with HPS, the mortality rate 
was approximately 41% after a mean follow-up of 2.5 years12. A prospective study 
on the prognostic significance of HPS showed that HPS is an independent predictor 
of survival, and mortality correlates with HPS severity. As the presence of HPS 
independently worsens the prognosis of cirrhotic patients, its presence should 
influence clinical management.  
                 If patients are on the waiting list for liver transplantation, the presence of 
HPS should be combined with the MELD (model for end-stage liver disease) score to 
accelerate the process for liver transplantation.  
                 A retrospective study by Krowka et al39 reported an improvement or 
normalization of hypoxemia in about 80% of patients after liver transplantation. A 
prospective study by Battaglia et al 42also demonstrated resolution of intrapulmonary 
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shunting in patients with HPS after liver transplantation. It is thus considered that HPS 
may be reversed after liver transplantation. The pulmonary vascular changes after 
successful transplantation show a slow remodeling process that may take a long time 
for symptom relief. It has been found that the lower the preoperative PaO2, the longer 
the time to decrease the alveolar-arterial pressure gradient and to improve arterial 
oxygenation.  
                 However, retrospective data show that there is a higher mortality rate after 
liver transplantation in patients with HPS than in those without HPS. Unique 
postoperative complications in patients with HPS have been described, which include 
pulmonary hypertension45,46, embolic cerebral hemorrhage47 and postoperative 
deterioration in oxygenation. These unique postoperative complications, along with 
delayed resolution of hypoxemia, are implicated in the higher mortality rate. For 
patients with severe preoperative hypoxemia (PaO2 ≤50 mmHg) and significant 
intrapulmonary shunting (Tc-99m MAA shunt fraction ≥20%), the mortality rate may 
increase further after liver transplantation39, 48. 
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AIMS AND OBJECTIVES 
 
1) To evaluate the Prevalence and  clinical  profile of  
hepatopulmonary syndrome in a tertiary care hospital 
 
2) To study the clinical spectrum of  HPS in cirrhotic patients  
 
3) To correlate severity of HPS with child Pugh score.   
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MATERIALS AND METHODS 
Setting: Department of medicine, medicalgastroenterology Government Rajaji 
hospital and Madurai medical college, Madurai. 
Design of study: Prospective analytical study. 
Period of study: November 2006 to April 2007 
Ethical committee approval: The present project was approved by the ethical 
committee. 
Criteria for selection of subjects: 
Rigid criteria were adopted for inclusion and exclusion of cases and controls 
for the present study. The details are furnished below. 
Inclusion criteria:  
1. All the cirrhosis patients confirmed by clinical, biochemical, ultrasound 
imaging. Liver biopsy was not done 
Exclusion criteria:  
1. Patients with known cardiovascular and respitatory diseases 
2. Other co morbid conditions which could explain hypoxemia 
3. Those with hepatic encephalopathy, bedridden patients, patients with active 
uncontrolled upper gastrointestinal hemorrhage 
4. Active smokers 
5. Patients having intra cardiac shunts in echocardiography 
6. Patients who were not willing to participate in the study. 
7. Children below 12 years. 
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Consent: 
Informed consent was obtained from all those who participated in the study. 
Materials: 
Thus a total of 73 cases that satisfied the inclusion and exclusion criteria stated 
above were taken up for the study.   
Methods:  
Selected sociodemographic, clinical and laboratory data were collected from 
the both inpatients and out patients of department of medicine and 
medicalgastroenterology and recorded in a pro forma. 
Socio demographic data comprised of: 
- age 
- sex 
- locality 
- occupation 
Clinical data comprised of: 
              -    Dyspnea 
              -    Platypnoea 
              -    H/o Alcoholism, drugs 
- Cyanosis 
- Clubbing 
- Jaundice 
- Ascites 
- systemic examination 
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Laboratory data included: 
- Hb ,TC,DC 
- Urine - albumin, deposits, Sugar 
- Blood Sugar 
- Urea 
- Creatinine 
- Liver function tests  
- Prothrombin time 
- Viral markers – HbsAg, AntiHCVAb 
- Electrolytes 
- ARTERIAL BLOOD GAS ANALYSIS 
- ECG, CHEST X RAY 
- Imaging studies 
- OGD 
- USG ABDOMEN 
- Contrast enhanced echocardiography(CEE) 
 
CEE procedure (using Aloka SSD 4000) was carried out in all patients to detect 
the presence of IPVD. A three way cannula and intra cath was fixed to the 
antecubital vein of the right forearm. Initial M-mode and 2-D echocardiography 
and colour Doppler study were carried out to exclude the presence of intracardiac 
shunts. Micro agitated saline was prepared in the injecting syringe and 10ml was 
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injected rapidly into the veins of the right forearm. Both right and left heart 
chambers were visualized on 2-D echocardiography to look for the appearance of 
the contrast. The study was repeated at the same sitting with M-mode 
echocardiography. The timing of appearance of the contrast in the left heart 
chambers following it’s appearance in the right heart chambers, in terms of heart 
beats, was documented. Appearance of the contrast in the left heart chambers 3-6 
beats after it’s appearance on the right side was taken as evidence of 
intrapulmonary shunting.  
ABG test was performed (using SIEMENS ANALYZER) in patients vertical 
position, the oxygenation saturation, arterial blood oxygen, (A-a) O2 gradient and 
were evaluated. 
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Definitions  
Child’s classification was done according to Child –Turcotte-Pugh score 
Parameter  
 
                         Numerical score 
1 2 3 
Ascites None  Slight  Moderate  
Encephalopathy  None  Slight /moderate Moderate/severe
Bilirubin (mg/dl)        <2           2 – 3          >3 
Albumin (g/dl)      >3.5       2.8 – 3.5        <2.8 
Prothrombintime(Seconds 
increased) 
1 - 3 4 – 6 >6 
 
    Total numerical score                             Child- Turcotte-Pugh score 
              5 – 6                                                                A 
              7 – 9                                                                B 
             10 – 15                                                             C 
Criteria for Alcoholic liver disease  
                Defined as intake of 40 – 80 gm of alcohol per day for minimum of 10 
years 
Clinical HPS  
Clinical HPS was diagnosed in a patient with positive CEE and Po2 
below 80mmHg.  
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Subclinical HPS  
Positive CEE and Po2 between 80mmHg -90mmHg were taken as sub 
clinical HPS.  
IPVDS  
Positive CEE and Po2 >90 mmHg were taken as Intrapulmonary vascular 
dilatation syndrome (IPVDS). 
Conflict of interest:  
There was no conflict of interest. 
support: 
Nil. 
Statistical analysis: 
          Data were entered in Microsoft Excel spread sheet and analyzed utilizing 
the software - epidemiological information package 2002 (Epi Info 2002)- 
developed by centre for disease control and prevention, Alaska for World Health 
Organization. Range, mean, standard deviation and ‘p’ values were calculated 
using this package.  Significance was considered if the ‘p’ value was below 0.05. 
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OBSERVATIONS AND RESULTS 
 
Table 1 
 
Age composition 
 
Age Group in years Total no Cases
No. %  
< 30  3 4.1 
31-40  12 16.4 
41-50  18 24.7 
51-60  20 27.4 
61-70  14 19.2 
> 70  6 8.2 
Total  73 100 
Mean  52.2 yrs 
S.D.  13.0 yrs 
 
Total of 73 patients were studied .age of cases ranges from 24years to 78 years 
 
Mean age was 52.2 ± 13 years 
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Table 2  
 
Sex composition       
 
 
          Among 73 cases studied there were 57 males and 16 females 
 
  
Sex composition 
78%
22%
MALES FEMALES
 
 
Sex Cases 
No. % 
Males 57 78.1 
Females 16 21.9 
Total 73 100 
30 
 
Aetiology of cirrhosis 
Among 73 cirrhotic 34 were alcoholics, HBs antigen was present in 6 patients, and 
Anti HCV antibody was present in 6 patients, In other 27 patients aetiology was 
not known. 
The tables were given below. 
Table 3 
Alcoholism 
Alcoholism 
34
39
0
5
10
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20
25
30
35
40
YES NO  
Alcoholism Cases 
No. % 
Yes 34 46.6 
No 39 53.4 
Total 73 100 
31 
 
 
Table 4 
HBsAntigen 
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HBs Antigen Cases 
No. % 
Present 6 8.2 
Absent 67 91.8 
32 
 
Table5 
AntiHCVAntibody 
 
Anti HCV Antibody Cases 
No. % 
Present 6 8.2 
Absent 67 91.8 
 
Anti HCV Antibody 
8%
92%
PRESENT ABSENT
 
 
 
33 
 
 
Table 6 
Clinical features 
Clinical features HPS(N=9) SUB HPS(N=6) IPVDS(N=17) p 
No. % No % No %  
Dyspnea 8 88.9 0 0 8 47.0 0.001 
Platypnea 2 22.2 0 0 0 0 0.07 
Cyanosis 9 100 0 0 0 0 0.0024 
Clubbing 7 77.8 2 33.3 3 17.6 0.009 
Spider naevi 2 22.2 0 0 0 0 0.04 
 
Commonest symptom was dyspnea which occurs in 88.9 % of patients with 
HPS, 47% of patients with IPVDS. Platypnea was present in 2 patients of HPS 
and was not present in subclinical HPS or IPVDS patients.  
 
All the patients of HPS had cyanosis. Clubbing was seen in 77.8% of HPS, 
33.3% of subclinical HPS, 17.6% of IPVDS patients respectively. 
 
 Dyspnea, cyanosis, clubbing, Spider naevi were significantly higher in HPS 
than other two groups. 
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Table 7  
Child's classification    
 
 
 
 
 
 
Among 73 patients 25(34.2%) were in child A, 37(50.7%) were in child B, 
11(15.1%) were in child C. 
CHILD’S CLASSIFICATION 
 
 
Child's Classification Cases 
No. % 
A 25 34.2 
B 37 50.7 
C 11 15.1 
Total 73 100 
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Table 8 
Contrast echo 
Contrast Echo Cases 
No. % 
Positive 32 43.8 
Negative 41 56.2 
Total 73 100 
 
Contrast echo was positive in 32 patients (43.8%) and was negative in 41 patients 
(56.2%) 
32
41
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CONTRAST ECHO
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Table 9 
Relationship between child’s classification and contrast echo 
 
 
 
 
 
 
 
There was no significant correlation between positive CEE and child’s classification 
6
19
19
18
7
4
0
5
10
15
20
25
30
35
40
%
 O
F 
C
A
SE
S
A B C
CHILD'S CLASSIFICATION
 
 
       Child's Classification                   Contrast Echo 
Positive Negative 
No. % No. % 
           A (25)    6 24 19 76 
           B (37)   19 51.4 18 48.6 
           C (11)    7 63.6 4 36.4 
’p’ 0.0666 (not Significant) 
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Table 10 
Relationship between Child's classification, PaO2 and Contrast Echo  
Child's classification and PaO2 Contrast Echo 
Positive Negative 
No. % No. % 
A (25) 
PaO2 < 80 
PaO2 80-90 
PaO2 >90 
 
1 
- 
5 
 
4 
- 
20 
 
3 
3 
13 
 
12 
12 
52 
Total 6 24 19 76 
B (37) 
PaO2 < 80 
PaO2 80-90 
PaO2 >90 
 
3 
5 
11 
 
8.1 
13.5 
29.7 
 
5 
4 
9 
 
13.5 
10.8 
24.3 
Total 19 51.3 18 48.7 
C (11) 
PaO2 < 80 
PaO2 80-90 
PaO2 >90 
 
5 
1 
1 
 
45.5 
9.1 
9.1 
 
1 
1 
2 
 
9.1 
9.1 
18.1 
Total 7 63.7 4 36.3 
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In child A out of 25 patients 6 had positive CEE in which one had pao2 < 80mmHg 
and 5 had pao2 > 90 mmHg. 
In child B out of 37 patients 19 had positive CEE in which 3 had pao2 <80, 5 had pao2 
between 80-90, 11 had pao2 > 90 mmHg 
In child C out of 11 patients 7 had positive CEE in which 5 had pao2 <80, I had pao2 
between 80-90, and I had pao2 > 90 mmHg. 
Table 11 
Prevalence of HPS 
 
 
 
 
 
 
Among 73 patients 9 (12.3%) had clinical HPS, 6 (8.2%) had sub clinical HPS, 17 
(23.3%) had IPVDS.  
CLINICAL SPECTRUM No OF PATIENTS %              N=73 
CLINICAL HPS       9   12.3 
SUBCLINICAL HPS       6    8.2 
IPVDS      17    23.3 
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Table 12 
Relationship between HPS and age 
Clinical spectrum Age in years 
Mean S.D. 
Clinical HPS (9) 53.89 14.13 
Sub clinical HPS (6) 47.33 7.94 
IPVDS (17) 53.47 11.71 
‘p’ 0.4594 (Not significant) 
 
There is no significant relationship between HPS and age 
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Mean Age
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Table 13 
Relationship between HPS and gender 
 
Clinical spectrum 
Sex 
Males Females 
No. % No. % 
Clinical HPS (9) 8 88.9 1 11.1 
Sub clinical HPS (6) 5 83.3 1 16.7 
IPVDS (17) 11 64.7 6 35.3 
             P 0.0723 not significant 
 
There is no significant relationship between HPS and gender 
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Table 14 
RELATIONSHIP BETWEEN HPS AND CHILD’S CLASSIFICATION 
Clinical Spectrum Child’s A  Child’s B      Child’s C 
Clinical HPS (9) 1(11.1%) 3(33.3%)     5(55.6%)       
SubclinicalHPS (6) 0         5(83.3%)       1(16.7%)        
IPVDS (17) 5(29.4%)     11(64.7%)       1(5.9%)      
 P        0.0626 not significant 
In child A Prevalence of HPS, subclinical HPS, IPVDS were 11.1%, 0, 
and 29.4% respectively. In child B Prevalence of HPS, subclinical HPS, IPVDS 
were 33.3%, 83.3%, 64.7% respectively. In child C Prevalence of HPS, 
subclinical HPS, IPVDS were 55.6%, 16.7%, 5.9% respectively. 
 
There is no significant correlation between child’s classification and 
occurrence of HPS 
0
2
4
6
8
10
12
Child
A
Child
B 
Child
C
IPVDS
Subclinic
al HPS
Clinical
HPS
 
42 
 
Table 15 
RELATIONSHIP BETWEEN HPS AND Alcoholism  
 
Clinical spectrum 
Alcoholism 
Yes No 
No. % No. % 
Clinical HPS (9) 6 66.7 3 33.3 
Sub clinical HPS (6) 3 50 3 50 
IPVDS (17) 6 35.3 11 64.7 
                                            
                                               P       0.0721 (not significant) 
6
3 3 3
6
11
0
2
4
6
8
10
12
Clinical
HPS (9)
Sub
clinical
HPS (6)
IPVDS
(17)
Yes
No
 
Six cases of clinical HPS, three cases of subclinical HPS, six cases of IPVDS 
were occurring in alcoholics. 
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Table 16 
Relationship between HPS and HBsAg 
 
 
Clinical spectrum 
Hb S Antigen 
Present Absent 
No. % No. % 
Clinical HPS (9) 2 22.2 7 77.8 
Sub clinical HPS (6) 2 33.3 4 66.7 
IPVDS (17) 1 5.9 16 94.1 
 
P             0.1030 not significant 
 
HBsAg was positive in two cases of clinical HPS, two cases of subclinical HPS 
and one case of IPVDS. 
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Table 17 
Relationship between HPS and HCV 
 
Clinical spectrum 
Anti HCV Antibody 
Present Absent 
No. % No. % 
Clinical HPS (9) - - 9 100 
Sub clinical HPS (6) 1 16.7 5 83.3 
IPVDS (17) 3 17.6 14 82.4 
 
p                            0.1376 not significant 
 
AntiHCV Antibody was present in three cases of IPVDS, one case of 
subclinical HPS, and none of clinical HPS patients.  
 
Aetiology of cirrhosis had no significant correlation with HPS 
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DISCUSSION 
Hepatopulmonary syndrome includes the triad of liver disease, arterial blood 
deoxygenation and intra pulmonary pulmonary shunts. 
Among 73 cases studied the mean age of patient was 52.2 ± 13 years with a 
range of 24 to 78 years. 
Regarding sex distribution male female ratio was 3: 1.since alcoholic liver 
disease is most common cause of cirrhosis in our country, alcoholism is more 
prevalent in males. This explains higher incidence of cirrhosis in males. 
Dyspnea 
In our study among 73 patients 31 (42.46%) had symptom of dyspnea, 16 
(51.6%) of those showed evidence of intrapulmonary shunt. H.S Hira et al (2003) 
found that 60% had symptom of dyspnea and (55.5%) showed evidence of shunt 48. 
Dyspnea was present in 88.9% of clinical HPS patients, 47% of IPVDS patients and 
none of subclinical HPS patients. P schenk et al (2002) stated that dyspnea was present 
in 57% of compared with 8% of subclinical HPS and 6% of patients without HPS51. 
Sarin et al (2006) showed dyspnea was present in 84.6% of HPS patients54. In our 
study platypnea was occur in 2 of 9 (22.2%) HPS  patients. This suggested that 
dyspnea was a reasonably sensitive but poorly specific clinical indicator of 
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intrapulmonary shunt. In the absence of any cardiopulmonary disease this symptom 
could suggest a pulmonary vascular complication of liver disease. 
Cyanosis 
In our study all the 9 patients of HPS and none among remaining 64 cases were 
found to have cyanosis showing 100% sensitivity and specificity. 
This is parallel with the observation made by H.S Hira et al (2003)48. It is likely that 
observation was an exaggeration of the true usefulness of this marker and could have 
resulted from the strict exclusion criteria for cardiopulmonary diseases. 
Clubbing 
In our study Clubbing was present in 7 of 9 (77.8%) of clinical HPS, 1 (33.3%) 
patient of subclinical IPVDS patients. Only 2 among remaining 41 patients showed 
clubbing. If we take HPS alone, presence of clubbing showed sensitivity of 77.8% and 
specificity of 92%. Hira et al(2003) had found that presence of clubbing showed 
sensitivity and specificity of 100% and 96% respectively48. In sarin et al (2006) 
clubbing was present in 92.3% 0f HPS patients54. In our study spider naevi was 
present in 2 of 9 (22.2%) HPS patients and was not present in remaining patients. In 
sarin et al (2006) spider naevi was present in 61.5% of HPS patients54. 
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Contrast echo 
In our study Contrast echo was positive in 32 of 73 (43.8%) patients. In Hira et 
al(2003) positive CEE was 33.34%, in sarin et al(2006) it was 30.3% , P schenk et 
al(2002) it was 34%,  mimidis KP(1998) et al it was 10.7%52, Anand AC et al(2001) it 
was 27%50, Binay K de et al(2000) it was 8.9%49.The reason for higher number of 
positive contrast echo in present study may be that majority of patients 31 0f 73 
selected were presented with dyspnea and patients associated with cardiopulmonary 
disease leading to hypoxemia were excluded. There is no significant correlation 
between child’s classification and positive contrast echocardiography. 
Hypoxemia 
           Hypoxemia caused by intrapulmonary shunting in sitting position was found in 
15 (20.5%) patients. Hypoxemia without shunt in sitting position was found in17 
(23.3%). Hypoxemia without shunt was higher than in with shunt. This is parallel with 
the observation made by culafic  Dj et al(2000)53 .Hypoxemia is common in patients 
with chronic liver disease. A rare cause is HPS. Because other abnormalities (eg 
ascites) or minor shunts that couldn’t be detected by contrast echo may coexist in 
cirrhotic patients and contribute to respiratory insufficiency. Measurement of lowered 
PO2 alone is not sufficient to make diagnosis of HPS   
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Prevalence of HPS 
           In our study prevalence of HPS was 12.2%, subclinical HPS was 8.2%, IPVDS 
was 23.2%.sarin et al (2006) had found that prevalence of HPS, subclinical HPS and 
IPVDS were 9.8%, 20.5%, 30.3% respectively. In Hira et al (2003) prevalence of HPS 
was 16.67%. Amir Houshang mohammad Alizadeh et al (2006) had found that 
prevalence of HPS and IPVDS were 18.5%, 13% respectively56.In Anand AC et al 
(2001) prevalence of HPS was 17.5% and IPVD was 27%50. In Binay K de et al 
(2000) prevalence of HPS was 8.9%. 
There is no significant relationship between HPS and age, sex, aetiology 
Regarding aetiology in our syudy most common aetiology was alcohol, but Amir 
Houshang Alizadeh et al(2006) had found that most common aetiology was HBV, but 
there was no significant relation56. In Anand AC et al(2001) Age, sex, duration of 
symptoms were not different in patients with HPS50. 
           Correlation between HPS and child’s classification was controversial. In our 
study among 9 cases of clinical HPS, Five occur in child C, Three in child B, One in 
child A, though child score was higher in clinical HPS group but did not reach 
statistical significance. This observation was consistent with earlier reports. Same 
results were observed in sarin et al(2006)54. Hira et al(2003) showed that child’s 
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grading of liver disease did not influence the incidence of HPS and IPVDS48. Binay k 
de et al (2000) showed that there was no clear relationship with severity of cirrhosis by 
child’s grading49. In P schenk et al (2002) child’s grading correlated significantly with 
severity of HPS. Interestingly studies conducted by sood N et al (2001) observed that 
50 patients were studied for intrapulmonary shunt but none had evidence of IPVD. 
IPVD was not observed in their study55. 
           Failure to recognize HPS can be serious because progressive decline in 
oxygenation can occur despite stable liver function at a mean 2.5 years after onset of 
dyspnea,41% mortality has been reported . Another reason to recognize HPS early is 
that it is treatable. The treatment of choice for cirrhotic patients, however is orthotopic 
liver transoplantation , but this is often complicated by intractable post operative 
hypoxemia. Current evidence indicates that a successful outcome is possible in the 
presence of post operative hypoxemia, but morbidity and mortality remain high. 
           Our study emphasizes that early detection of HPS in cirrhotic patients helps in 
reduction in morbidity and mortality and thereby increasing prognosis.        
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CONCLUSION 
 
¾ HPS is well known but often under recognized common complication in 
cirrhosis 
¾ Dyspnea was commonest symptom in HPS patients. HPS should be 
suspected in a cirrhotic who complaining of dyspnea and particularly 
Platypnea. 
¾ Cyanosis was a strong predictive marker of HPS if strict exclusion criteria 
for cardiopulmonary diseases were followed. 
¾ Contrast enhanced echo and ABG were an easy and cheap method of 
identifying shunts in pulmonary circuit. 
¾ Age, Sex, Aetiology of cirrhosis had no influence on presence of  HPS 
¾ There was no correlation between child’s classification and HPS 
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SUMMARY 
 
 
Hepatopulmonary syndrome includes the triad of liver disease, arterial blood 
deoxygenation and intra pulmonary pulmonary shunts. This study was conducted to 
evaluate the Prevalence and clinical profile of hepatopulmonary syndrome and to 
study the clinical spectrum of HPS in cirrhotic patients . 
After institutional ethical clearance, with an informed consent and with rigid 
criteria, 73 patients were selected carefully and were evaluated on social, clinical and 
laboratory aspects. The data were entered in Micro soft Excel spread sheet and 
analyzed statistically. 
                There were 57 males and 16 females; Mean age was 52.2 ± 13 years. 
Among 73 patients 25 were in child A, 37were in child B, 11were in child C. 
Commonest symptom was dyspnea which occurs in 88.9 % of patients with HPS, 47% 
of patients with IPVDS.  Dyspnea was a reasonably sensitive but poorly specific 
clinical indicator of intrapulmonary shunt. In the absence of any cardiopulmonary 
disease this symptom could suggest a pulmonary vascular complication of liver 
disease 
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             All the patients of HPS had cyanosis. Cyanosis was a strong predictive 
marker of HPS if strict exclusion criteria for cardiopulmonary diseases were 
followed. 
             Dyspnea, cyanosis, clubbing, Spider naevi were significantly higher in HPS 
than other two groups. 
             Hypoxemia is common in patients with chronic liver disease. A rare cause is 
HPS. Because other abnormalities (eg ascites) or minor shunts that couldn’t be 
detected by contrast echo may coexist in cirrhotic patients and contribute to 
respiratory insufficiency. Measurement of lowered PO2 alone is not sufficient to make 
diagnosis of HPS. 
In our study prevalence of HPS was 12.2%, subclinical HPS was 8.2%, and 
IPVDS was 23.2% 
There is no significant relationship between HPS and age, sex, aetiology. 
Regarding aetiology in our study most common aetiology was alcohol. Though child 
score was higher in clinical HPS group but did not reach statistical significance.  
 
POSTIVE CONTRAST ENHANCED ECHO 
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NEGATIVE CONTRAST ENHANCED ECHO 
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APPENDIX II 
PRO FORMA 
Case No: 
Name: 
Age: 
Sex: 
IP No: 
Address: (rural/urban) 
Occupation: (agricultural/nonagricultural) 
Duration : 
H/o present illness: 
1. Abdominal distention 
2. Abdominal pain  
3. Jaundice 
4. Hemetemesis 
5. Melena 
6. Fever 
7. Dyspnea, Platypnea 
8. Altered sensorium 
Past History 
Jaundice, blood transfusion,surgery, chronic lung disease, RHD/IHD, Tuberculosis, 
DM,HT 
Personal History 
Alcoholic-type ,quantity,duration, smoker 
General examination 
Consciousness, orientation, anemia, cyanosis, clubbing, pedal edema, 
lymphadenopathy 
Signs of liver cell failure – jaundice, spidernaevi, gynecomastia, alopecia 
Vitals: 
 
 Pulse rate. 
 BP. 
 Respiratory rate. 
 Weight. 
 Temperature. 
Systemic examination: 
• CVS 
• RS 
• ABDOMEN 
• CNS 
Investigations: 
 
◊ Hb, TC, DC. 
◊ Urine examination 
◊ Blood grouping and typing. 
◊ Urea, creatinine and electrolytes 
◊ Liver function tests 
◊ Viral markers 
◊ Chest Xray 
◊ Ultrasound Abdomen 
◊ OGD 
◊ Contrast enhanced echo 
◊ Arterial Blood Gas analysis 
 
 
Child pugh score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX III - MASTER 
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Child's 
Classification
Contrast 
Echo PaO2mmHg PaO2 mm Hg P(A-a)O2 gradient
1 Alexander 38 1 2 1 2 2 2 1 1 1 B Positive 48.2 < 80 58.9
2 A. Ramakrishnan 47 1 2 2 2 1 2 2 2 2 A Negative 78 < 80 33
3 Mariappan 45 1 2 2 2 2 2 2 2 2 B Positive 82.8 80-90 25.2
4 Chitrai Thirunal 58 1 1 2 2 1 2 2 2 2 C Positive 95.7 > 90 15.5
5 Haseena begam 45 2 2 2 2 1 2 2 2 2 A Negative 88.3 80-90 23.7
6 Srinivasan 44 1 1 2 2 1 2 2 2 2 C Negative 87.8 80-90 23
7 Rayanathar 53 1 2 2 2 2 2 2 2 2 B Negative 91.5 > 90 17.2
8 Dhanabalan 47 1 1 2 2 2 2 2 2 2 B Negative 99.2 > 90 10.5
9 Ayesa beevi 65 2 2 2 2 2 2 2 2 2 B Positive 103.4 > 90 7
10 Manoharan 52 1 1 2 2 1 1 2 2 2 A Negative 98.3 > 90 11.8
11 Venkatakrishnan 60 1 2 2 2 1 2 2 2 2 B Negative 72.2 < 80 0
12 Santhana lakshmi 45 2 2 2 2 2 2 2 2 2 B Negative 93.9 > 90 0
13 Cholalingam 55 1 2 2 2 2 2 2 2 2 B Negative 101.1 > 90 7.2
14 Somasundaram 73 1 2 2 2 2 2 2 2 2 B Positive 110.9 > 90 0
15 Ramesh 40 1 1 2 2 2 2 2 2 2 B Positive 87.3 80-90 28.3
16 Sivashankar 42 1 2 1 2 2 2 2 2 2 B Positive 83.1 80-90 31.6
17 Balasaraswathy 54 2 2 2 1 2 2 2 2 2 B Positive 101 > 90 8
18 Manoharan 49 1 1 2 2 1 2 2 2 2 B Positive 100.9 > 90 12.2
19 Xavier 58 1 1 2 2 1 2 2 1 2 B Negative 63.6 < 80 56
20 Venkatesan 78 1 2 2 2 2 2 2 2 2 A Negative 94.1 > 90 21.4
21 Sriramabu 62 1 1 2 2 2 2 2 2 2 B Positive 93.5 > 90 130
22 Arumugum 59 1 2 2 1 1 2 2 2 2 B Negative 112.6 > 90 7.8
23 Selva natarajar 45 1 2 2 1 1 2 2 2 2 B Negative 130.2 > 90 0
24 Mohan Rajam 41 1 2 2 2 2 2 2 2 2 A Negative 110.5 > 90 0
25 Periyasamy 66 1 2 2 2 1 2 2 2 2 A Negative 104.4 > 90 9.5
26 Rajendrar 47 1 1 2 2 2 2 2 1 2 A Positive 99.2 > 90 11.9
27 Kanchana 40 2 2 2 2 1 2 2 2 2 A Negative 97.9 > 90 12.7
28 Somasundaes 69 1 1 2 2 1 2 2 2 2 B Negative 69.1 < 80 42.5
29 Kamal nisha 40 2 2 2 2 2 2 2 2 2 A Positive 98.7 > 90 56.1
30 Cauvery 71 2 2 2 2 1 2 2 2 2 A Positive 90.5 > 90 27.1
31 Veeramohan 47 1 2 2 2 2 2 2 2 2 B Negative 84.3 80-90 27.6
32 Antony dass 51 1 2 2 2 1 2 2 2 2 B Positive 96.5 > 90 20.4
33 Rajendran 40 1 1 2 2 1 2 2 2 2 B Negative 88.8 80-90 565.4
34 Nayalakshmi 56 2 2 2 2 2 2 2 2 2 B Negative 93.3 > 90 16.7
35 Vijayaragavan 65 1 2 2 2 1 2 2 2 2 C Negative 113 > 90 6.1
36 Suriyakumar 45 1 1 2 2 2 2 2 2 2 A Negative 91.9 > 90 28.7
37 Elango 53 1 1 2 2 1 2 2 1 2 B Positive 94 > 90 301.2
38 Pandian 64 1 1 2 2 1 1 2 1 2 C Positive 77.4 < 80 32.4
39 Andalagar 38 1 1 2 2 1 2 1 1 1 C Positive 64.4 < 80 13
40 Muthuraman 45 1 1 2 2 2 2 2 1 2 B Positive 81.3 80-90 32.9
41 Alagarsamy 59 1 Oce 2 2 2 2 2 1 2 A Positive 115.3 > 90 5
42 Chellammal 55 2 2 1 1 2 2 2 2 B Positive 93 > 90 22.7
43 James mary 62 2 2 2 2 2 2 2 2 2 A Negative 85.8 80-90 22.9
44 Manikandan 34 1 1 1 2 2 2 2 2 2 B Negative 106.3 > 90 0
45 Eanappan 35 1 1 2 2 2 2 2 2 2 B Negative 68.6 < 80 549
46 Kasthuri 55 2 2 2 2 2 2 2 2 2 A Negative 104.3 > 90 11.3
47 Rajapandi 48 1 1 2 2 1 2 2 2 2 A Negative 85.6 80-90 20
48 Narayanan 67 1 1 2 2 2 2 2 2 2 A Negative 49.1 < 80 60.2
49 Mayilshakti 55 2 2 2 2 2 2 2 2 2 A Negative 78.3 < 80 31.5
50 Rajamannar 65 1 2 2 2 2 2 2 2 2 A Negative 98.7 > 90 6.3
51 Saravanan 38 1 1 2 2 2 2 2 2 2 C Negative 98.5 > 90 19.2
52 Ramasamy 45 1 2 1 2 2 2 2 2 2 B Positive 95.4 > 90 15.7
53 Muthummal 78 2 2 2 2 2 2 2 2 2 B Negative 65.8 80-90 15.3
54 Arumugum 68 1 2 2 2 1 2 1 1 2 A Positive 76.1 < 80 40.1
55 Meeneesvaran 24 1 2 2 2 2 2 2 2 2 A Negative 100.3 > 90 0
56 Murugesan 40 1 1 2 2 2 2 2 2 2 B Positive 100.1 > 90 12
57 Murugaboopathy 48 1 1 2 2 1 2 1 1 2 C Positive 68.4 < 80 44.5
58 Syed sulaiman 52 1 1 2 2 2 2 2 2 2 C Positive 64.8 < 80 55
59 Chokkalingam 67 1 1 2 2 1 2 1 1 2 B Positive 56.2 < 80 21.6
60 Balakrishnan 56 1 2 2 2 2 2 2 2 2 B Negative 102.6 > 90 8.7
61 Annadikanan 36 1 1 2 2 2 2 2 2 2 B Negative 71.3 < 80 39.6
62 Gunasekaran 42 1 1 2 2 1 2 2 2 2 C Negative 64.5 < 80 92.6
63 Durairaj 62 1 1 2 2 2 2 2 1 2 C Positive 87.5 80-90 29.6
64 Dhanalakshmi 72 2 2 1 2 1 2 2 2 2 B Positive 73.9 < 80 37.8
65 Arumugam 54 1 1 2 2 2 2 2 2 2 A Negative 95.5 > 90 13.2
66 Gopal 60 1 1 2 2 1 2 2 2 2 A Negative 90.9 > 90 17.4
67 Chellam 74 1 1 2 2 1 2 2 2 2 B Negative 88.3 80-90 29.3
68 Murugesan 38 1 1 2 2 1 2 1 1 2 C Positive 65.6 < 80 26.1
69 Krishnamoorthy 27 1 2 2 2 1 2 2 2 2 A Positive 105.9 > 90 2.1
70 Muthiah 62 1 1 2 2 2 2 2 2 2 A Negative 91.8 > 90 23
71 Jeyalakshmi 60 2 2 2 1 2 2 2 2 2 B Positive 93.7 > 90 29.5
72 Lakshmi 50 2 2 1 1 2 2 2 2 2 B Positive 82.2 80-90 533.3
73 Jeyasingam 64 1 1 2 2 2 2 2 2 2 A Negative 96.7 > 90 29.5
2- Absent1 - Present
2- Sex Female2- Sex Male 
